Literature DB >> 11181537

Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor.

C J MacKenzie1, E M Lutz, M S Johnson, D N Robertson, P J Holland, R Mitchell.   

Abstract

The vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 (VPAC(2)) receptor was shown to induce both [(3)H]inositol phosphate ([(3)H]InsP)and cAMP production in transfected COS7 cells and in GH(3) cells where it is natively expressed. Neither cholera toxin nor forskolin could elicit an equivalent [(3)H]InsP response, suggesting independent coupling of the two pathways. The VPAC(2) receptor-mediated [(3)H]InsP response was partially inhibited by pertussis toxin (Ptx) and by the G beta gamma-sequestering C-terminal fragment of GRK2 (GRK2-ct) in COS7 and GH(3) cells, whereas responses of control receptors were unaffected. Blockers of receptor-activated Ca(2+) influx pathways (Co(2+) and SKF 96365) also partially inhibited VPAC(2) receptor-mediated [(3)H]InsP responses. This inhibition was not present in the component of the response remaining after Ptx treatment. A range of blockers of voltage-sensitive Ca(2+) channels were ineffective, consistent with the reported lack of these channels in COS7 cells. The data suggest that the VPAC(2) receptor may couple to phospholipase C through both Ptx-insensitive and Ptx-sensitive G proteins (G(q/11) and G(i/o), respectively) to generate [(3)H]InsP. In addition to G beta gamma, G(i/o) activation appears to require receptor-activated Ca(2+) entry. This is consistent with the possibility that not only G alpha(q/11)-responsive and G beta gamma-responsive isoforms of phospholipase C but also Ca(2+)-responsive forms may contribute to the overall [(3)H]InsP response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181537     DOI: 10.1210/endo.142.3.8013

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Modeling the VPAC2-activated cAMP/PKA signaling pathway: from receptor to circadian clock gene induction.

Authors:  Haiping Hao; Daniel E Zak; Thomas Sauter; James Schwaber; Babatunde A Ogunnaike
Journal:  Biophys J       Date:  2005-12-09       Impact factor: 4.033

2.  The role of VIP in cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Megan E Foldenauer; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-07       Impact factor: 4.799

3.  Neurotrophic actions of PACAP-38 and LIF on human neuroblastoma SH-SY5Y cells.

Authors:  T K Monaghan; C Pou; C J MacKenzie; R Plevin; E M Lutz
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

4.  Inhibitory pathways in the circular muscle of rat jejunum.

Authors:  Gwen Vanneste; Patrick Robberecht; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

Review 5.  Pleiotropic pituitary adenylate cyclase-activating polypeptide (PACAP): Novel insights into the role of PACAP in eating and drug intake.

Authors:  Andrew T Gargiulo; Genevieve R Curtis; Jessica R Barson
Journal:  Brain Res       Date:  2019-12-26       Impact factor: 3.252

6.  Characterisation of the mouse vasoactive intestinal peptide receptor type 2 gene, Vipr2, and identification of a polymorphic LINE-1-like sequence that confers altered promoter activity.

Authors:  G Steel; E M Lutz
Journal:  J Neuroendocrinol       Date:  2007-01       Impact factor: 3.627

Review 7.  Signal Transduction by VIP and PACAP Receptors.

Authors:  Ingrid Langer; Jérôme Jeandriens; Alain Couvineau; Swapnil Sanmukh; Dorota Latek
Journal:  Biomedicines       Date:  2022-02-09

8.  Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.

Authors:  Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

9.  PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases.

Authors:  T K Monaghan; C J Mackenzie; R Plevin; E M Lutz
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

Review 10.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

Authors:  Carmen Martínez; Yasmina Juarranz; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; David Castro; Amalia Lamana; Mario Mellado; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.